Terns Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of TERN-601 Oral GLP-1 Receptor Agonist for Treatment of Obesity

Phase 1 trial underway for Terns’ first oral GLP-1R agonist candidate for obesity, with 28-day proof of concept data anticipated in 2H24

Oral GLP-1R agonist offers potential for weight loss and improved convenience compared to currently marketed injectables

Excerpt from the Press Release:

FOSTER CITY, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) — Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, obesity and non-alcoholic steatohepatitis (NASH), today announced that the first participant has been dosed in the Phase 1 clinical trial of TERN-601, the Company’s oral small-molecule glucagon-like peptide-1 receptor, or GLP-1R, agonist for the treatment of obesity.

“We are excited to initiate this first-in-human study of our oral GLP-1R agonist, TERN-601, as we believe it represents a potentially meaningful alternative to the currently marketed injectable GLP-1R agonist treatments,” said Erin Quirk, MD, president and head of research and development at Terns. “TERN-601 represents our first internally discovered small molecule GLP-1R agonist, which is designed to be administered orally once daily with a competitive profile for weight loss, both as a monotherapy and as part of a potential all oral combination treatment for obesity.”

“We are encouraged by the prospects for our obesity franchise and look forward to reporting initial 28-day weight loss proof of concept data from the Phase 1 trial of TERN-601, which is anticipated in the second half of 2024. We also have ongoing discovery efforts in obesity with our TERN-600 series of additional small molecule GLP-1R agonists and our TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators, which have the potential to be combined with GLP-1R agonists. These programs along with TERN-501, our highly selective THR-β agonist in development for the treatment of NASH, aim to meaningfully improve clinical outcomes for patients battling metabolic diseases, with better potential tolerability, accessibility and ease-of-use than currently available treatments,” added Dr. Quirk.

Click the button below to read the entire Press Release:

Continue Reading The Press Release